Results 1 to 10 of about 33,833 (238)

Investigation of bedaquiline heteroresistance among Mycobacterium tuberculosis isolates from Pakistan

Microbiology Spectrum
Bedaquiline is a key drug recommended by the WHO for the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB, and its use could potentially shorten treatment duration with improved outcomes.
Faiqa Rashid, Shaukat Iqbal, Sabira Tahseen, Yanlin Zhao   +3 more
doaj   +2 more sources

Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria [PDF]

Nature Communications
Bedaquiline, an ATP synthase inhibitor, is the spearhead of transformative therapies against drug-resistant Mycobacterium tuberculosis. Here, we use remission spectroscopy to measure the energy-transducing cytochromes within unperturbed, respiring ...
Suzanna H. Harrison, Rowan C. Walters, Chen-Yi Cheung, Roger J. Springett, Gregory M. Cook, Morwan M. Osman, James N. Blaza   +6 more
doaj   +2 more sources

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.

PLOS Global Public Health, 2023
Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the global prevalence of resistance to these drugs and the impact of ...
Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun   +9 more
doaj   +2 more sources

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis

Genome Medicine
Background Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of ...
Camus Nimmo, Arturo Torres Ortiz, Cedric C. S. Tan, Juanita Pang, Mislav Acman, James Millard, Nesri Padayatchi, Alison D. Grant, Max O’Donnell, Alex Pym, Ola B. Brynildsrud, Vegard Eldholm, Louis Grandjean, Xavier Didelot, François Balloux, Lucy van Dorp   +15 more
doaj   +2 more sources

Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study. [PDF]

Clin Infect Dis
Background Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains.
Singla R, Khan S, Silsarma A, Chavan V, Mahajan R, Mansoor H, Devan RK, Singla N, Bhalla M, Kumar G, Singh P, Iyer A, Morales M, Devkota SC, Dalal A, Spencer H, Isaakidis P.   +16 more
europepmc   +2 more sources

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia

Emerging Infectious Diseases
Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and ...
Gunar Günther, Lusia Mhuulu, Azaria Diergaardt, Viola Dreyer, Maria Moses, Kaarna Anyolo, Nunurai Ruswa, Mareli Claassens, Stefan Niemann, Emmanuel Nepolo   +9 more
doaj   +2 more sources

Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia

International Journal of Mycobacteriology
Background: Bedaquiline is one of the core drugs used to treat multidrug-resistant TB (MDR-TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used.
Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Susi Subay, Suko Hari Adiono   +5 more
doaj   +2 more sources

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.

New England Journal of Medicine, 2022
BACKGROUND The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high.
F. Conradie, T. Bagdasaryan, S. Borisov, P. Howell, L. Mikiashvili, N. Ngubane, A. Samoilova, Sergey Skornykova, E. Tudor, E. Variava, P. Yablonskiy, D. Everitt, G. Wills, E. Sun, M. Olugbosi, E. Egizi, Mengchun Li, A. Holsta, Juliano Timm, A. Bateson, A. Crook, S. Fabiane, R. Hunt, T. McHugh, C. Tweed, S. Foraida, C. Mendel, M. Spigelman   +27 more
semanticscholar   +1 more source

Role of therapeutic drug monitoring in pulmonary infections : use and potential for expanded use of dried blood spot samples [PDF]

, 2015
Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment.
Akkerman, Onno W, Alffenaar, Jan-Willem C, Bolhuis, Mathieu S, Hofman, Susan, Koster, Remco A, Stove, Christophe, van Assen, Sander   +6 more
core   +18 more sources

Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis

BMC Infectious Diseases, 2022
Background This retrospective cohort study assessed benefits and risks of bedaquiline treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating safety, effectiveness, drug utilization and emergence of resistance to ...
Helen Pai, Norbert Ndjeka, Lawrence Mbuagbaw, Koné Kaniga, Eileen Birmingham, Gary Mao, Lori Alquier, Kourtney Davis, Arianne Bodard, Abeda Williams, Magalie Van Tongel, Florence Thoret-Bauchet, Shaheed V. Omar, Nyasha Bakare   +13 more
doaj   +1 more source